Interviews

Mack Roach III, MD, discusses concerns about how tariffs and restrictions on international collaboration could negatively affect cancer research and treatment.

Nini Wu, MD, MBA, discusses the future of technology in community oncology, particularly highlighting the pervasive topic of artificial intelligence.

Stuart J. Schnitt, MD, discussed how AI enhances cancer diagnoses and the need for professional oversight, ethical clarity, and equitable adoption.

Christopher Schenewerk, MD, addresses the taboo topic of how to help health care professionals struggling with addiction.

Ariel Lopez-Chavez, MD, discusses the role of comprehensive genomic profiling in small cell lung cancer management.

Ciara Freeman, MD, PhD, discusses the challenges of incorporating anito-cel into the treatment protocol for patients with multiple myeloma.

Douglas A. Tremblay, MD, discusses the importance of quality-of-life data from treating patients with polycythemia vera with ropeginterferon alfa-2b-njft.

Ciara Freeman, MD, PhD, discusses anito-cel's unique functions and benefits for treating multiple myeloma.

Nini Wu, MD, MBA, discusses how community oncology practices can leverage technology to maximize efficiency and reduce administrative burdens.

Madhur Nayan, MD, PhD, discusses a new machine learning model developed to enhance prostate cancer screening.

Christopher Schenewerk, MD, discussed his history with alcohol abuse and how he works to break down the taboo of substance abuse among medical professionals.

Dong Chen, MD, PhD, discusses the obstacles and opportunities for growth in posttreatment cancer detection.

Dong Chen, MD, PhD, discusses the most recent advancements in posttreatment cancer detection.

Colin P.N. Dinney, MD, PhD, discussed updated analyses of the BOND-003 and CORE-001 trials in bladder cancer.

Jack Khouri, MD, discusses data from a multicenter study of teclistamab in patients with relapsed/refractory multiple myeloma who had prior exposure to BCMA-directed therapy.

Andrew Kuykendall, MD, discusses data from a phase 2 trial of fedratinib for the treatment of myeloproliferative neoplasms.

Colin P.N. Dinney, MD, provides some background on translational analyses from the BOND-003 and CORE-001 trials.

Ruben Olivares, MD, discusses the first remote transcontental HIFU therapy for prostate cancer.

Nicole A. Cipriani, explores the clinical relevance of the BRAF p.V600E mutation in papillary thyroid carcinoma and its potential role in guiding treatment decisions.

Aditya Shreenivas, MD, MS, discusses the clinical trial that led to the FDA approval of penpulimab in nasopharyngeal carcinoma.

Stuart J. Schnitt, MD, discussed artificial intelligence enhancements roadblocks, and potential integration for cancer diagnostics with Targeted Oncology.

Enriqueta Felip, MD, PhD, discusses how results from the phase 3 3475A-D77 trial evaluating subcutaneous pembrolizumab vs intravenous pembrolizumab, plus chemotherapy, for the treatment of metastatic NSCLC may impact patient experience and clinical workflow.

Aditya Shreenivas, MD, MS, discusses findings from the clinical trial supporting the FDA approval of penpulimab in nasopharyngeal carcinoma.

Yelena Y. Janjigian, MD, discusses how to manage the potential adverse events of pembrolizumab when using the recently approved combination of pembrolizumab plus trastuzumab and chemotherapy.

Ruben Olivares, MD, discusses the important implications of the first transcontinental robot-assisted focal therapy procedure for prostate cancer.

Amandeep Salhotra, MD, discusses data from the phase 3 Precision-T trial of Orca-T in patients with advanced hematologic malignancies.

Olalekan O Oluwole, MD, MBBS, discusses a study investigating shorter monitoring times post CAR T therapy.

Quoc-Dien Trinh, MD, MBA, discusses a sub-analysis of the phase 3 ARANOTE trial, which focused on Black patients with metastatic hormone-sensitive prostate cancer.

Amandeep Salhotra, MD, discusses Orca-T and its evaluation in the phase 3 Precision-T trial in patients with advanced hematologic malignancies.